Join our pre-Series A round to fund our dry AMD program
SeaBeLife is currently finalizing its pre-Series A funding round, targeting a total of €2 million. The goal is to finance … Lire la suite
Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye
download PDF SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues … Lire la suite
SeaBeLife receives Orphan Drug Designation (ODD) from EMA for treatment of acute liver injuries
Download pdf Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways … Lire la suite
27th Carrés 2023 – SEABELIFE Innovation Award
For the 27th edition of the “Soirée des Carrés”, the Morlaix region’s business club, Domaine de Treuscoat, SeaBeLife and La … Lire la suite
LSX Inv€$tival Showcase
📢 SeaBeLife Biotech will be attending the 8th annual LSX Inv€$tival Showcase Morgane Rousselot, our founder and CEO, and @Jean-Pierre … Lire la suite
SeaBeLife receives close to €1.4M deep tech financing from Bpifrance
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute … Lire la suite
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death. Roscoff, May 17th, 2021. SeaBeLife, … Lire la suite
SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death.
SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death. Roscoff, June 15, 2020. SeaBeLife, a pharmaceutical … Lire la suite